For instance, novel cyclic peptides P6 and P9 have shown high specificity for EGFRvIII-expressing cells, enhancing targeted drug delivery and cytotoxicity in non-small-cell lung cancer (NSCLC) and glioblastoma models [41]. This evidence concerns the gene EXOSC8 and non-small cell lung carcinoma.